• 1
    Walker MD, Alexander E Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg. 1978; 49: 333343.
  • 2
    Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med. 1980; 303: 13231329.
  • 3
    Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of Grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. Br J Cancer. 1991; 64: 769774.
  • 4
    Chang CH, Horton J, Schoenfeld D, et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer. 1983; 52: 9971007.
  • 5
    Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas Grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer. 1981; 47: 649652.
  • 6
    Levin VA, Silver P, Hannigan J, et al. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys. 1990; 18: 321324.
  • 7
    Green SB, Byar DP, Walker MD, et al. Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep. 1983; 67: 121132.
  • 8
    Fine HA, Dear KB, Loeffler JS, et al. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults [see comments]. Cancer. 1993; 71: 25852597.
  • 9
    Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter Phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol. 1999; 17: 27622771.
  • 10
    Yung WK. Temozolomide in malignant gliomas. Semin Oncol. 2000; 27: 2734.
  • 11
    Yung WK, Albright RE, Olson J, et al. A Phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000; 83: 588593.
  • 12
    Galanis E, Buckner JC, Burch PA, et al. Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North Central Cancer Treatment Group results. J Clin Oncol. 1998; 16: 29532958.
  • 13
    Friedman HS, Petros WP, Friedman AH, et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol. 1999; 17: 15161525.
  • 14
    Friedman HS. Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis. Semin Oncol. 2000; 27: 3540.
  • 15
    Burton E, Prados M. New chemotherapy options for the treatment of malignant gliomas. Curr Opin Oncol. 1999; 11: 157161.
  • 16
    Newlands ES, Blackledge GR, Slack JA, et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer. 1992; 65: 287291.
  • 17
    O'Reilly SM, Newlands ES, Glaser MG, et al. Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer. 1993; 29A: 940942 [published erratum appears in: Eur J Cancer. 1993;29A:1500].
  • 18
    Bower M, Newlands ES, Bleehen NM, et al. Multicentre CRC Phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol. 1997; 40: 484488.
  • 19
    Friedman HS, McLendon RE, Kerby T, et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol. 1998; 16: 38513857.
  • 20
    Brandes AA, Ermani M, Basso U, et al. Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: a Phase II study. Oncology. 2002; 63: 3841.
  • 21
    Stupp R, Dietrich PY, Ostermann Kraljevic S, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol. 2002; 20: 13751382.
  • 22
    Trent S, Kong A, Short SC, et al. Temozolomide as second-line chemotherapy for relapsed gliomas. J Neurooncol. 2002; 57: 247251.
  • 23
    Groves MD, Puduvalli VK, Hess KR, et al. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol. 2002; 20: 13831388.
  • 24
    Yung WK, Harris MI, Bruner JM, et al. Intravenous BCNU and AZQ in patients with recurrent malignant gliomas. J Neurooncol. 1989; 7: 237240.
  • 25
    Watne K, Hannisdal E, Nome O, et al. Combined intra-arterial and systemic chemotherapy for recurrent malignant brain tumors. Neurosurgery. 1992; 30: 223227.
  • 26
    Brandes AA, Scelzi E, Zampieri P, et al. Phase II trial with BCNU plus alpha-interferon in patients with recurrent high-grade gliomas. Am J Clin Oncol. 1997; 20: 364367.
  • 27
    Hildebrand J, De Witte O, Sahmoud T. Response of recurrent glioblastoma and anaplastic astrocytoma to dibromodulcitol, BCNU and procarbazine—a Phase-II study. J Neurooncol. 1998; 37: 155160.
  • 28
    Hochberg F, Prados M, Russell C, et al. Treatment of recurrent malignant glioma with BCNU-fluosol and oxygen inhalation. A Phase I-II study. J Neurooncol. 1997; 32: 4555.
  • 29
    Newton HB, Junck L, Bromberg J, et al. Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failure. Neurology. 1990; 40: 17431746.
  • 30
    Rodriguez LA, Prados M, Silver P, et al. Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors. Cancer. 1989; 64: 24202423.
  • 31
    Yung WK, Mechtler L, Gleason MJ. Intravenous carboplatin for recurrent malignant glioma: a Phase II study. J Clin Oncol. 1991; 9: 860864.
  • 32
    Curran WJ Jr., Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials [see comments]. J Natl Cancer Inst. 1993; 85: 704710.
  • 33
    Khan RB, Raizer JJ, Malkin MG, et al. A Phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro-oncol. 2002; 4: 3943.